Table 2.

Randomized fixed-ratio combination trials

Study	Duration (weeks)	Baseline therapy	Treatment	Comparator	Relative HbA1c change vs. comparator (all p < 0.0001) (%)
Watada et al. [79]	26	OAD	iGlarLixi	Lixisenatide	−1.07
Terauchi et al. [80]	26	OAD	iGlarLixi	iGlar	− 0.63
Kaneto et al. [81]	26	Basal insulin + Met	iGlarLixi	iGlar	− 0.74
Yuan et al. [82]	30	Basal insulin ± OAD	iGlarLixi	iGlar	− 0.7

IDegLira insulin glargine/liraglutide, IGlarLixi insulin glargine/lixisenatide, iGlar insulin glargine, Lira liraglutide, Met metformin, OAD oral anti-diabetic agents